- Home
- SGP vs HELP Comparison
SGP vs HELP Comparison
Compare SGP & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGP | HELP |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.4M | 854.9M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGP | HELP |
|---|---|---|
| Price | $24.92 | $11.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $44.00 | $40.12 |
| AVG Volume (30 Days) | 108.2K | ★ 1.6M |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.06 | $3.76 |
| 52 Week High | $30.56 | $15.15 |
Technical Indicators
Market Signals| Indicator | SGP | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 49.79 |
| Support Level | $24.85 | $11.26 |
| Resistance Level | $26.29 | $14.35 |
| Average True Range (ATR) | 1.43 | 0.69 |
| MACD | -0.37 | -0.25 |
| Stochastic Oscillator | 29.19 | 43.46 |
Price Performance
Historical ComparisonAbout SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.